INVA - Innoviva Inc Stock Price, Fair Value and News

18.54USD+0.35 (+1.92%)Market Closed

Market Summary

USD18.54+0.35

Market Closed

1.92%

INVA Stock Price

View Fullscreen

INVA RSI Chart

INVA Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

11.58

Price/Sales (Trailing)

3.72

EV/EBITDA

6.52

Price/Free Cashflow

7.61

INVA Price/Sales (Trailing)

INVA Profitability

EBT Margin

63.57%

Return on Equity

14.21%

Return on Assets

7.89%

Free Cashflow Yield

13.13%

INVA Fundamentals

INVA Revenue

Revenue (TTM)

311.6M

Rev. Growth (Yr)

1.48%

Rev. Growth (Qtr)

-9.72%

INVA Earnings

Earnings (TTM)

100.0M

Earnings Growth (Yr)

4.78%

Earnings Growth (Qtr)

284.07%

Breaking Down INVA Revenue

Last 7 days

7.9%

Last 30 days

13.9%

Last 90 days

21.5%

Trailing 12 Months

42.8%

How does INVA drawdown profile look like?

INVA Financial Health

Current Ratio

10.42

Debt/Equity

0.63

Debt/Cashflow

0.34

INVA Investor Care

Buy Backs (1Y)

4.67%

Diluted EPS (TTM)

2.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	311.6M	0	0	0
2023	310.9M	290.4M	290.4M	310.5M
2022	376.7M	361.6M	346.5M	331.3M
2021	350.6M	364.3M	378.1M	391.9M
2020	284.5M	299.4M	322.3M	336.8M
2019	263.8M	260.8M	264.9M	261.0M
2018	229.1M	237.6M	250.7M	261.0M
2017	149.9M	176.0M	191.3M	217.2M
2016	71.2M	93.0M	112.8M	133.6M
2015	16.1M	25.8M	38.4M	53.9M
2014	5.5M	6.5M	7.5M	8.4M
2013	5.3M	5.1M	4.8M	4.5M
2012	145.3M	140.3M	135.3M	5.6M
2011	24.3M	24.4M	24.4M	24.5M
2010	0	0	0	24.2M
2009	0	0	0	24.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

WEBSITE	inva.com
INDUSTRY	Biotechnology
EMPLOYEES	101

Innoviva Inc Frequently Asked Questions

What is the ticker symbol for Innoviva Inc? What does INVA stand for in stocks?

INVA is the stock ticker symbol of Innoviva Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Innoviva Inc (INVA)?

As of Fri Jul 26 2024, market cap of Innoviva Inc is 1.16 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INVA stock?

You can check INVA's fair value in chart for subscribers.

Is Innoviva Inc a good stock to buy?

The fair value guage provides a quick view whether INVA is over valued or under valued. Whether Innoviva Inc is cheap or expensive depends on the assumptions which impact Innoviva Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INVA.

What is Innoviva Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, INVA's PE ratio (Price to Earnings) is 11.58 and Price to Sales (PS) ratio is 3.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INVA PE ratio will change depending on the future growth rate expectations of investors.